Balance Sheet
Cash Flow Statement
AmortizationAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Net Income (2016 - 2025)

Historic Net Income for Dr Reddys Laboratories (RDY) over the last 17 years, with Q4 2025 value amounting to $133.6 million.

  • Dr Reddys Laboratories' Net Income fell 1965.63% to $133.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $316.9 million, marking a year-over-year decrease of 3647.85%. This contributed to the annual value of $671.0 million for FY2025, which is 44.91% up from last year.
  • Dr Reddys Laboratories' Net Income amounted to $133.6 million in Q4 2025, which was down 1965.63% from $183.3 million recorded in Q1 2025.
  • Dr Reddys Laboratories' Net Income's 5-year high stood at $183.3 million during Q1 2025, with a 5-year trough of $152.0 in Q3 2022.
  • Over the past 5 years, Dr Reddys Laboratories' median Net Income value was $154.0 million (recorded in 2022), while the average stood at $131.6 million.
  • In the last 5 years, Dr Reddys Laboratories' Net Income crashed by 9999.98% in 2022 and then skyrocketed by 11778634501.85% in 2023.
  • Over the past 5 years, Dr Reddys Laboratories' Net Income (Quarter) stood at $11.0 million in 2021, then soared by 962.09% to $116.8 million in 2022, then surged by 45.52% to $170.0 million in 2023, then fell by 2.21% to $166.3 million in 2024, then decreased by 19.66% to $133.6 million in 2025.
  • Its Net Income was $133.6 million in Q4 2025, compared to $183.3 million in Q1 2025 and $166.3 million in Q4 2024.